<DOC>
	<DOC>NCT01107093</DOC>
	<brief_summary>Evaluation of the effect of a single dose of CDB-2914, as compared to placebo, administered after the onset of the LH surge on the outcome of the leading ovary follicle: - echographic follicle rupture - inhibition of follicle rupture - luteal phase progesterone levels - anovulatory progesterone levels</brief_summary>
	<brief_title>Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge</brief_title>
	<detailed_description />
	<mesh_term>Rupture</mesh_term>
	<criteria>Women of good general health aged 18 35 years Not at risk of pregnancy Regular menstrual cycles of 2435 days duration Not pregnant Intact uterus and ovaries Haemoglobin â‰¥ 11 g/dl Normal laboratory tests and normal TSH Willing to abstain from any use of hormonal contraception until study completion No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since termination of previous hormonal contraception Had at least one complete menstrual cycle (2 menses) following delivery, miscarriage or induced abortion Able to give voluntary, written informed consent, and agreeing to observe all study requirements for 5 complete menstrual cycles Current participation in any other trial of an investigational medicine Known hypersensitivity to the ingredients of the test active substances or excipients Suspected hyperplasia or carcinoma of the endometrium Current pregnancy as confirmed by positive serum betahCG at screening Desire to get pregnant before the planned end of the study participation Currently breastfeeding Abnormal Pap smear Cancer (past history of any carcinoma or sarcoma) Known or suspected alcoholism or drug abuse Abnormal thyroid status Body mass index &gt; 32 Current use of hormonal contraception Use of hormonal emergency contraception since last menstrual period Severe asthma insufficiently controlled by oral glucocorticoids Hereditary galactose intolerance, Lapp lactase deficiency, or glucosegalactose malabsorption</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>